Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to steer clear of vascular events in men and women along with raised C-reactive protein. N Engl J Med 2008;359:2195–2207.
Food and Drug Administration: FDA drug safety communication: crucial safety label adjustments to cholesterol-lowering statin drugs. http://ift.tt/1BtxPMj. Published July 3, 2012. Accessed March 20, 2012.
European Medicines Agency. HMG-CoA reductase inhibitorsVrisk of brand-new onset diabetes. http://ift.tt/1XI7gwA. Published January 10, 2012. Accessed March 20, 2012.
Goldberg R, La Belle P, Zupkis R, et al. Comparison of the effects of lovastatin and gemfibrozil on lipids and glucose manage in non-insulin-dependent diabetes mellitus. Am J Cardiol 1990;66:16B–21B.
Johnson BF, LaBelle P, Wilson J, et al. Effects of lovastatin in diabetic patients treated along with chlorpropamide. Clin Pharmacol Ther 1990;48:467–472.
Ohrvall M, Lithell H, Johansson J, et al. A comparison in between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients along with noninsulin-dependent diabetes mellitus and hyperlipoproteinemia. Metabolism 1995;44:212–217.
Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the progression of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001;103:357–362.
Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735–742.
Mora S, Glynn RJ, Hsia J, et al. Statins for the primary prevention of cardio events in women along with raised high-sensitivity C-reactive healthy protein or dyslipidemia: outcomes from the Justification for the Usage of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation 2010;121:1069–1077.
Ridker PM, Pradhan A, MacFadyen JG, et al. cardio incentives and diabetes pitfalls of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012;380:565–571.
Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events along with atorvastatin in hypertensive patients that have actually standard or lower-than-standard cholesterol levels concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149–1158.
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol levels lowering along with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7–22.
Long-Term Intervention along with Pravastatin in Ischaemic Illness (LIPID) Study Group. Prevention of cardio events and death along with pravastatin in patients along with coronary heart Illness and a broad range of first cholesterol levels levels. N Engl J Med 1998;339:1349–1357.
Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly people at risk of vascular Illness (PROSPER): a randomised controlled trial. Lancet 2002;360:1623–1630.
Kostapanos MS, Milionis HJ, Agouridis AD, et al. Rosuvastatin treatment is associatedwith an raise in insulin resistance in hyperlipidaemic patients along with impaired fasting glucose. Int J Clin Pract 2009;63:1308–1313.
Koh KK, Quon MJ, Han SH, et al. Atorvastatin triggers insulin resistance and boosts ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol 2010;55:1209–1216.
Coleman CI, Reinhart K, Kluger J, et al. The effect of statins on the progression of new-onset form 2 diabetes: a meta-analysis of randomized controlled trials. Curr Med Res Opin 2008;24:1359–1362.
Rajpathak SN, Kumbhani DJ, Crandall J, et al. Statin therapy and risk of producing form 2 diabetes: a meta-analysis. Diabetes Care 2009;32:1924–1929.
Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes along with intensive dose compared along with moderate-dose statin therapy: a meta-analysis. JAMA 2011;305:2556–2564.
Navarese EP, Buffon A, Andreotti F, et al. Meta-analysis of impact of various types and doses of statins on new-onset diabetes mellitus. Am J Cardiol 2013;111:1123–1130.
Zaharan NL, Williams D, Bennett K. Statins and risk of treated incident diabetes in a primary care population. Br J Clin Pharmacol 2013;75:1118–1124.
Cederberg H, Stancakova A, Yaluri N, et al. Increased risk of diabetes along with statin treatment is associated along with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia 2015;58:1109–1117.
Culver AL, Ockene IS, Balasubramanian R, et al. Statin Usage and risk of diabetes mellitus in postmenopausal women in the Women’s Healthiness Initiative. Arch Intern Med 2012;172:144–152.
Mansi I, Frei CR, Wang CP, et al. Statins and new-onset diabetes mellitus and diabetic complications: a retrospective cohort study of US healthy and balanced adults. J Gen Intern Med 2015;30:1599–1610.
Waters DD, Ho JE, DeMicco DA, et al. Predictors of new-onset diabetes in patients treated along with atorvastatin: outcomes from 3 big randomized clinical trials. J Am Col Cardiol 2011;57:1535–1545.
Sattar NA, Ginsberg H, Ray K, et al. The Usage of statins in people at risk of producing diabetes mellitus: evidence and recommendations for clinical practice. Atheroscler Suppl 2014;15:1–15.
Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009;301:2129–2140.
Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol 2007;99:410–414.
Ruscica M, Macchi C, Morlotti B, et al. Statin therapy and related risk of new-onset form 2 diabetes mellitus. Eur J Intern Med 2014;25:401–406.
Brault M, Ray J, Gomez YH, et al. Statin treatment and new-onset diabetes: a review of proposed mechanisms. Metabolism 2014;63:735–745.
Yada T, Nakata M, Shiraishi T, et al. Inhibition by simvastatin, yet not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion as a result of blockade of L-form Ca2+ channels in rat islet beta-cells. Br J Pharmacol 1999;126:1205–1213.
Ganesan S, Ito MK. Coenzyme Q10 ameliorates the reduction in GLUT4 transporter expression induced by simvastatin in 3T3-L1 adipocytes. Metab Syndr Relat Disord 2013;11:251–255.
Nakata M, Nagasaka S, Kusaka I, et al. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 2006;49:1881–1892.
Besseling J, Kastelein JJ, Defesche JC, et al. Association in between familial hypercholesterolemia and prevalence of form 2 diabetes mellitus. JAMA 2015;313:1029–1036.
Carter AA, Gomes T, Camacho X, et al. Risk of incident diabetes among patients treated along with statins: population based study. BMJ 2013;346:f2610.
Teramoto T, Shimano H, Yokote K, et al. brand-new evidence on pitavastatin: efficacy and safety in clinical studies. Expert Opin Pharmacother 2010;11:817–828.
Yamakawa T, Takano T, Tanaka S, et al. Encourage of pitavastatin on glucose tolerance in patients along with form 2 diabetes mellitus. J Atheroscler Thromb 2008;15:269–275.
Odawara M. Effect of pitavastatin on the incidence of diabetes in Japanese people along with impaired glucose tolerance. Diabetologia 2013;56:S59.
Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol levels to minimize atherosclerotic cardio risk in adults: a report of the American College of Cardiology/American Heart Association Task Pressure on technique Guidelines. Circulation 2014;129(25 Suppl 2):S1–S45.
Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association advice for patient-centered management of dyslipidemia: section 1Vexecutive summary. J Clin Lipidol 2014;8:473–488.
Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes.NEnglJMed2015;372:2387–2397.
Hansen M, Sonne DP, Knop FK. Bile acid sequestrants: glucose-lowering mechanisms and efficacy in form 2 diabetes. Curr Diab Rep 2014;14:482.
Ong KL, Barter PJ, Waters DD. cardio drugs that raise the risk of new-onset diabetes. Am Heart J 2014;167:421–428.
Roth EM, McKenney JM, Hanotin C, et al. Atorvastatin along with or free of an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 2012;367:1891–1900.
Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014;370:1809–1819.
KnowlerWC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of form 2 diabetes along with way of life intervention or metformin. N Engl J Med 2002;346:393–403.
Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on way of life management to minimize cardio risk: a report of the American College of Cardiology/American Heart Association Task Pressure on technique Guidelines. J Am Coll Cardiol 2014;63(25 Pt B):2960–2984.
